IDXX · Idexx Laboratories Inc · Insider Trading
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-11-10 | FENNELL GEORGE |
Executive Vice President |
Convert↑
|
Common Stock
|
483 |
| 2026-11-10 | FENNELL GEORGE |
Executive Vice President |
Convert↓
Filing footnotes — Incentive Stock Option (right-to-buy) (Direct)
Grant of option to buy 706 shares of Issuer common stock that vested in one installment on February 14, 2022. |
Incentive Stock Option (right-to-buy)
|
706 |
| 2026-11-10 | FENNELL GEORGE |
Executive Vice President |
Convert↑
|
Common Stock
|
706 |
| 2026-11-10 | FENNELL GEORGE |
Executive Vice President |
Convert↓
Filing footnotes — Incentive Stock Option (right-to-buy) (Direct)
Grant of option to buy 483 shares of Issuer common stock that vests in one installment on February 14, 2024. |
Incentive Stock Option (right-to-buy)
|
483 |
| 2026-11-10 | FENNELL GEORGE |
Executive Vice President |
Convert↑
|
Common Stock
|
560 |
| 2026-11-10 | FENNELL GEORGE |
Executive Vice President |
Convert↓
Filing footnotes — Incentive Stock Option (right-to-buy) (Direct)
Grant of option to buy 560 shares of Issuer common stock that vested in one installment on February 14, 2023. |
Incentive Stock Option (right-to-buy)
|
560 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $703.04 to a high of $703.99 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
3,950 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $707.645 to a high of $708.59 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
1,840 |
| 2026-11-04 | Underberg Sharon E. |
EVP, GC & Corporate Secretary |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $688.70 to a high of $689.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
1,503 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Convert↓
Filing footnotes — Non-Qualified Stock Option (right-to-buy) (Direct)
Not applicable. Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2019. |
Non-Qualified Stock Option (right-to-buy)
|
25,140 |
| 2026-11-04 | Lane Michael |
Executive Vice President |
Sell↓
|
Common Stock
|
2,059 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
|
Common Stock
|
240 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $709.815 to a high of $710.63 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
1,501 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $706.60 to a high of $707.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
840 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $701.005 to a high of $701.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
4,540 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Convert↑
|
Common Stock
|
25,140 |
| 2026-11-04 | Lane Michael |
Executive Vice President |
Sell↓
Filing footnotes — Common Stock (Direct)
Includes a total of 31 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2026, June 30, 2026 and September 30, 2026. |
Common Stock
|
242 |
| 2026-11-04 | Underberg Sharon E. |
EVP, GC & Corporate Secretary |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $690.02 to a high of $690.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
1,055 |
| 2026-11-04 | JUNIUS DANIEL M |
Director |
Sell↓
|
Common Stock
|
500 |
| 2026-11-04 | JUNIUS DANIEL M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $705.26 to a high of $706.05 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
700 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $702.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
2,136 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $700.00 to a high of $700.80 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
1,667 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $710.82 to a high of $711.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
775 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $697.80 to a high of $698.77 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
1,945 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $698.92 to a high of $699.89 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
4,075 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $708.65 to a high of $709.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
1,300 |
| 2026-11-04 | Underberg Sharon E. |
EVP, GC & Corporate Secretary |
Convert↑
Filing footnotes — Common Stock (Direct)
Includes a total of 31 shares acquired under the Issuer's Employee Stock Purchase Plan on March 31, 2026, June 30, 2026 and September 30, 2026. |
Common Stock
|
8,906 |
| 2026-11-04 | Underberg Sharon E. |
EVP, GC & Corporate Secretary |
Convert↓
Filing footnotes — Non-Qualified Stock Option (right-to-buy) (Direct)
Not applicable. Grant of option to buy shares of Issuer common stock that vested in four annual installments beginning February 14, 2021. |
Non-Qualified Stock Option (right-to-buy)
|
8,906 |
| 2026-11-04 | Underberg Sharon E. |
EVP, GC & Corporate Secretary |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $687.70 to a high of $688.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
6,348 |
| 2026-11-04 | Lane Michael |
Executive Vice President |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $687.0701 to a high of $687.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
1,677 |
| 2026-11-04 | MAZELSKY JONATHAN JAY |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $711.845 to a high of $712.34 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
331 |
| 2026-10-30 | HOOLEY JOSEPH L |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the 'Plan') in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($26,250.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. |
Common Stock
|
48 |
| 2026-09-04 | Kingsley Lawrence D |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the weighted average price of the shares sold ranging from a low of $531.88 to a high of $532.14 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
Common Stock
|
2,203 |
| 2026-09-04 | Kingsley Lawrence D |
Director |
Convert↓
Filing footnotes — Non-Qualified Stock Option (right-to-buy) (Direct)
Not applicable. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on May 3, 2017. |
Non-Qualified Stock Option (right-to-buy)
|
2,203 |
| 2026-09-04 | Kingsley Lawrence D |
Director |
Convert↑
|
Common Stock
|
2,203 |
| 2026-08-20 | Emerson Andrew |
EVP, CFO and Treasurer |
Convert↑
Filing footnotes — Common Stock (Direct)
Includes a total of 20 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2026 and June 30, 2026. |
Common Stock
|
265 |
| 2026-08-20 | Emerson Andrew |
EVP, CFO and Treasurer |
Tax↓
|
Common Stock
|
86 |
| 2026-08-20 | Emerson Andrew |
EVP, CFO and Treasurer |
Convert↓
Filing footnotes — Incentive Stock Option (right-to-buy) (Direct)
Not applicable Grant of option to buy 1,190 shares of Issuer common stock that became exercisable in one installment on February 14, 2023. |
Incentive Stock Option (right-to-buy)
|
265 |
| 2026-07-30 | HOOLEY JOSEPH L |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the 'Plan') in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($27,280.22) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. |
Common Stock
|
49 |
| 2026-06-01 | FENNELL GEORGE |
Executive Vice President |
Convert↓
Filing footnotes — Restricted Stock Unit (Direct)
Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026. Not applicable. |
Restricted Stock Unit
|
639 |
| 2026-06-01 | FENNELL GEORGE |
Executive Vice President |
Tax↓
|
Common Stock
|
284 |
| 2026-06-01 | FENNELL GEORGE |
Executive Vice President |
Convert↑
|
Common Stock
|
639 |
| 2026-05-12 | JUNIUS DANIEL M |
Director |
Award↑
Filing footnotes — Restricted Stock Unit (Direct)
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
Restricted Stock Unit
|
234 |
| 2026-05-12 | HOOLEY JOSEPH L |
Director |
Award↑
Filing footnotes — Deferred Stock Unit (Direct)
Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. |
Deferred Stock Unit
|
234 |
| 2026-05-12 | Peacock Karen |
Director |
Award↑
Filing footnotes — Deferred Stock Unit (Direct)
Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. |
Deferred Stock Unit
|
234 |
| 2026-05-12 | SAMAD SAM |
Director |
Award↑
Filing footnotes — Deferred Stock Unit (Direct)
Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. |
Deferred Stock Unit
|
234 |
| 2026-05-12 | Kingsley Lawrence D |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right-to-buy) (Direct)
Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
Non-Qualified Stock Option (right-to-buy)
|
525 |
| 2026-05-12 | Vandebroek Sophie V. |
Director |
Award↑
Filing footnotes — Restricted Stock Unit (Direct)
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
Restricted Stock Unit
|
234 |
| 2026-05-12 | Claflin Bruce L. |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right-to-buy) (Direct)
Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
Non-Qualified Stock Option (right-to-buy)
|
525 |
| 2026-05-12 | Britt Irene Chang |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right-to-buy) (Direct)
Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
Non-Qualified Stock Option (right-to-buy)
|
525 |